デフォルト表紙
市場調査レポート
商品コード
966811

PTCL-NOS(非特定型末梢性T細胞リンパ腫):疫学洞察(2030年までの予測)

PTCL-NOS - Epidemiology Insight - 2030

出版日: 受注後作成 | 発行: DelveInsight Business Research LLP | ページ情報: 英文 100 Pages | 納期: 2~10営業日

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=115.93円
PTCL-NOS(非特定型末梢性T細胞リンパ腫):疫学洞察(2030年までの予測)
出版日: 受注後作成
発行: DelveInsight Business Research LLP
ページ情報: 英文 100 Pages
納期: 2~10営業日
  • 全表示
  • 概要
  • 図表
  • 目次
概要

当レポートは、世界主要7ヶ国(米国、欧州5ヶ国(ドイツ、フランス、イタリア、スペイン、英国)、日本)のPTCL-NOS(非特定型末梢性T細胞リンパ腫)について調査しており、疫学および予測、セグメント別の症例、診断例などの情報を提供しています。

目次

第1章 主な洞察

第2章 エグゼクティブサマリー

第3章 疾患の背景と概要

  • 概要
  • 兆候と症状
  • 病態生理学
  • 危険因子
  • 診断

第4章 患者の治療過程

第5章 疫学と患者人口

  • 疫学の主な調査結果
  • 前提条件と理論的根拠:主要7ヶ国
  • 疫学シナリオ:主要7ヶ国
    • 疫学シナリオ(2017-2030)
  • 米国疫学
  • 欧州5ヶ国別疫学
    • ドイツ疫学
    • フランス疫学
    • イタリア疫学
    • スペイン疫学
    • 英国疫学
  • 日本疫学

第6章 治療アルゴリズム、現在の治療、および医事

  • 治療と管理
  • 治療アルゴリズム

第7章 KOLの見解

第8章 アンメットニーズ

第9章 付録

  • 参考文献
  • レポートの調査手法

第10章 DelveInsightのサービス内容

第11章 免責事項

第12章 DelveInsightについて

図表

List of Tables

  • Table 1: PTCL-NOS Epidemiology in 7MM (2017-2030)
  • Table 2: PTCL-NOS Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Table 3: PTCL-NOS Epidemiology in the United States (2017-2030)
  • Table 4: PTCL-NOS Diagnosed and Treatable Cases in the United States (2017-2030)
  • Table 5: PTCL-NOS Epidemiology in Germany (2017-2030)
  • Table 6: PTCL-NOS Diagnosed and Treatable Cases in Germany (2017-2030)
  • Table 7: PTCL-NOS Epidemiology in France (2017-2030)
  • Table 8: PTCL-NOS Diagnosed and Treatable Cases in France (2017-2030)
  • Table 9: PTCL-NOS Epidemiology in Italy (2017-2030)
  • Table 10: PTCL-NOS Diagnosed and Treatable Cases in Italy (2017-2030)
  • Table 11: PTCL-NOS Epidemiology in Spain (2017-2030)
  • Table 12: PTCL-NOS Diagnosed and Treatable Cases in Spain (2017-2030)
  • Table 13: PTCL-NOS Epidemiology in the United Kingdom (2017-2030)
  • Table 14: PTCL-NOS Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Table 15: PTCL-NOS Epidemiology in Japan (2017-2030)
  • Table 16: PTCL-NOS Diagnosed and Treatable Cases in Japan (2017-2030)

List of Figures

  • Figure 1: PTCL-NOS Epidemiology in 7MM (2017-2030)
  • Figure 2: PTCL-NOS Diagnosed and Treatable Cases in 7MM (2017-2030)
  • Figure 3: PTCL-NOS Epidemiology in the United States (2017-2030)
  • Figure 4: PTCL-NOS Diagnosed and Treatable Cases in the United States (2017-2030)
  • Figure 5: PTCL-NOS Epidemiology in Germany (2017-2030)
  • Figure 6: PTCL-NOS Diagnosed and Treatable Cases in Germany (2017-2030)
  • Figure 7: PTCL-NOS Epidemiology in France (2017-2030)
  • Figure 8: PTCL-NOS Diagnosed and Treatable Cases in France (2017-2030)
  • Figure 9: PTCL-NOS Epidemiology in Italy (2017-2030)
  • Figure 10: PTCL-NOS Diagnosed and Treatable Cases in Italy (2017-2030)
  • Figure 11: PTCL-NOS Epidemiology in Spain (2017-2030)
  • Figure 12: PTCL-NOS Diagnosed and Treatable Cases in Spain (2017-2030)
  • Figure 13: PTCL-NOS Epidemiology in the United Kingdom (2017-2030)
  • Figure 14: PTCL-NOS Diagnosed and Treatable Cases in the United Kingdom (2017-2030)
  • Figure 15: PTCL-NOS Epidemiology in Japan (2017-2030)
  • Figure 16: PTCL-NOS Diagnosed and Treatable Cases in Japan (2017-2030)

The table of contents is not exhaustive; will be provided in the final report

目次
Product Code: DIEI1086

DelveInsight's 'PTCL-NOS - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted PTCL-NOS epidemiology in the 7MM, i.e., the United States, EU5 (Germany, Spain, Italy, France, and the United Kingdom), and Japan.

Geographies Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Study Period: 2017-2030

PTCL-NOS Understanding

The DelveInsight PTCL-NOS epidemiology report gives a thorough understanding of the PTCL-NOS by including details such as disease definition, symptoms, causes, pathophysiology, and diagnosis. It also provides treatment algorithms and treatment guidelines for PTCL-NOS in the US, Europe, and Japan. The report covers the detailed information of the PTCL-NOS epidemiology scenario in seven major countries (US, EU5, and Japan).

PTCL-NOS Epidemiology Perspective by DelveInsight

The PTCL-NOS epidemiology division provides insights about historical and current patient pool and forecasted trend for every seven major countries. The PTCL-NOS epidemiology data are studied through all possible division to give a better understanding of the Disease scenario in 7MM. The PTCL-NOS epidemiology segment covers the epidemiology data in the US, EU5 countries (Germany, Spain, Italy, France, and the UK), and Japan from 2017 to 2030. It also helps to recognize the causes of current and forecasted trends by exploring numerous studies, survey reports and views of key opinion leaders.

PTCL-NOS Detailed Epidemiology Segmentation

The PTCL-NOS epidemiology covered in the report provides historical as well as forecasted PTCL-NOS epidemiology scenario in the 7MM covering the United States, EU5 countries (Germany, Spain, Italy, France, and the United Kingdom) and Japan from 2017 to 2030.

The DelveInsight PTCL-NOS report also provides the epidemiology trends observed in the 7MM during the study period, along with the assumptions undertaken. The calculated data are presented with relevant tables and graphs to give a clear view of the epidemiology at first sight.

Scope of the Report:

  • The PTCL-NOS report covers a detailed overview explaining its causes, symptoms, classification, pathophysiology, diagnosis and treatment patterns
  • The PTCL-NOS Epidemiology Report and Model provide an overview of the risk factors and global trends of PTCL-NOS in the seven major markets (7MM:US, France, Germany, Italy, Spain, UK, and Japan)
  • The report provides insight about the historical and forecasted patient pool of PTCL-NOS in seven major markets covering the United States, EU5 (Germany, Spain, France, Italy, UK), and Japan
  • The report helps to recognize the growth opportunities in the 7MM with respect to the patient population
  • The report assesses the disease risk and burden and highlights the unmet needs of PTCL-NOS
  • The report provides the segmentation of the PTCL-NOS epidemiology

Report Highlights:

  • 11-Year Forecast of PTCL-NOS epidemiology
  • 7MM Coverage
  • Total Cases of PTCL-NOS
  • Total Cases of PTCL-NOS according to segmentation
  • Diagnosed cases of PTCL-NOS

KOL- Views

We interview, KOLs and SME's opinion through primary research to fill the data gaps and validate our secondary research. The opinion helps to understand the total patient population and current treatment pattern. This will support the clients in potential upcoming novel treatment by identifying the overall scenario of the indications.

Key Questions Answered

  • What will be the growth opportunities in the 7MM with respect to the patient population pertaining to PTCL-NOS?
  • What are the key findings pertaining to the PTCL-NOS epidemiology across 7MM and which country will have the highest number of patients during the forecast period (2017-2030)?
  • What would be the total number of patients of PTCL-NOS across the 7MM during the forecast period (2017-2030)?
  • Among the EU5 countries, which country will have the highest number of patients during the forecast period (2017-2030)?
  • At what CAGR the patient population is expected to grow in 7MM during the forecast period (2017-2030)?
  • What is the disease risk, burden and unmet needs of the PTCL-NOS?
  • What are the currently available treatments of PTCL-NOS?

Reasons to buy:

  • The PTCL-NOS Epidemiology report will allow the user to -
  • Develop business strategies by understanding the trends shaping and driving the global PTCL-NOS market
  • Quantify patient populations in the global PTCL-NOS market to improve product design, pricing, and launch plans
  • Organize sales and marketing efforts by identifying the age groups and sex that present the best opportunities for PTCL-NOS therapeutics in each of the markets covered
  • Understand the magnitude of PTCL-NOS population by its epidemiology
  • The PTCL-NOS Epidemiology Model developed by DelveInsight is easy to navigate, interactive with dashboards, and epidemiology based with transparent and consistent methodologies. Moreover, the model supports data presented in the report and showcases disease trends over 11-year forecast period using reputable sources

Key Assessments

  • Patient Segmentation
  • Disease Risk and Burden
  • Risk of disease by the segmentation
  • Factors driving growth in a specific patient population

Table of Contents

1. Key Insights

2. Executive Summary of PTCL-NOS

3. PTCL-NOS : Disease Background and Overview

  • 3.1. Introduction
  • 3.2. Sign and Symptoms
  • 3.3. Pathophysiology
  • 3.4. Risk Factors
  • 3.5. Diagnosis

4. Patient Journey

5. Epidemiology and Patient Population

  • 5.1. Epidemiology Key Findings
  • 5.2. Assumptions and Rationale: 7MM
  • 5.3. Epidemiology Scenario: 7MM
    • 5.3.1. PTCL-NOS Epidemiology Scenario in the 7MM (2017- 2030)
  • 5.4. United States Epidemiology
    • 5.4.1. PTCL-NOS Epidemiology Scenario in the United States (2017- 2030)
  • 5.5. EU-5 Country-wise Epidemiology
    • 5.5.1. Germany Epidemiology
      • 5.5.1.1. PTCL-NOS Epidemiology Scenario in Germany (2017- 2030)
    • 5.5.2. France Epidemiology
      • 5.5.2.1. PTCL-NOS Epidemiology Scenario in France (2017- 2030)
    • 5.5.3. Italy Epidemiology
      • 5.5.3.1. PTCL-NOS Epidemiology Scenario in Italy (2017- 2030)
    • 5.5.4. Spain Epidemiology
      • 5.5.4.1. PTCL-NOS Epidemiology Scenario in Spain (2017- 2030)
    • 5.5.5. United Kingdom Epidemiology
      • 5.5.5.1. PTCL-NOS Epidemiology Scenario in the United Kingdom (2017-2030)
  • 5.6. Japan Epidemiology
    • 5.6.1. PTCL-NOS Epidemiology Scenario in Japan (2017- 2030)

6. Treatment Algorithm, Current Treatment, and Medical Practices

  • 6.1. PTCL-NOS Treatment and Management
  • 6.2. PTCL-NOS Treatment Algorithm

7. KOL Views

8. Unmet Needs

9. Appendix

  • 9.1. Bibliography
  • 9.2. Report Methodology

10. DelveInsight Capabilities

11. Disclaimer

12. About DelveInsight

The table of contents is not exhaustive; will be provided in the final report